Single dose study to evaluate dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (5 mg, 10 mg and 20 mg) in healthy adult human subjects under fasting conditions.~To evaluate dose proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (5 mg, 10 mg and 20 mg) in healthy, adult, human subjects under fasting conditions.~To monitor the safety and tolerability of the subjects.~An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.